Publications found:
50,876
Sort by:
Cempra: “GAIN from Drugs for Bad Bugs”
US$ 140.00
Drug resistance is a growing concern worldwide and Cempra (CEMP) is one of our lead recommendations ... offer an attractive investment opportunity in this therapy class. CEMP’s lead drug, 1. Solithromycin (CEM-101, PhIII, CABP; PhII cUTI) ... released on 2nd July, 2012 on CEMP titled “GAIN from Drugs for Bad Bugs”
July 2012
9 pages
US Cardiac Device Market Analysis
US$ 1,000.00
The higher prevalence of cardiovascular diseases has become a cause of concern for the US healthcare authorities as mortalities tend to rise and economic burden keep increasing. It is estimated that t...
July 2012
75 pages
US Clinical Laboratory Testing Market Assessment
US$ 1,000.00
The US represents an attractive destination for healthcare services’ market segments, especially clinical lab testing, which has evolved as a major source of decisive factor for healthcare professiona...
July 2012
45 pages
Onyx Pharma – Kyprolis to Accelerate Growth
US$ 140.00
... events – cardiovascular toxicities and deaths associated with Kyprolis as expected. ONXX has finally succeeded in ... Nexavar (L, RCC, HCC, partnered with Bayer), Kyprolis, and Regorafenib (R, oral multi-kinase inhibitor, GIST ... on Jun 21, 2012 on Onyx Pharma titled “Onyx Pharma - Kyprolis to Accelerate Growth”
June 2012
4 pages
Celgene: Long-Term Prospects Intact but Competition Emerging!
US$ 140.00
... flat growth of Revlimid (L, RRMM, MDS), reported in its 1Q12, we expect Celgene (CELG) to meet its FY12 guidance (Total rev.: $5.4-$5.6b and EPS ... , please read our report, released on 12th June on CELG, titled “Long-Term Prospects Intact but Competition Emerging!”
June 2012
3 pages
VERTEX PHARMA - Time to Book Profits
US$ 140.00
Vertex (VRTX) has evolved from an innovator to a profitable Biotech but at the ... detail, please read our report released on 11th June, 2012 on Vertex titled “Time to Book Profits….!”
June 2012
4 pages
Prioritizing Generic Drug development pipeline – The top Fifty Opportunities
US$ 5,000.00
... crucial aspects of growth strategy for a generic company or an Active Pharmaceutical Ingredient manufacturing ... recently approved or are in late stage development / Filed but with significantly success probability ... / therapeutic value compared to marketed drugs Anticipated competition in the therapy and ...
June 2012
100 pages
Coal Liquefaction Industry in United States
US$ 350.00
... . Aruvian's R'search’s report on the Coal Liquefaction Industry in the United States is a complete coverage report which focuses on the basics of coal liquefaction, its history, challenges and barriers ...
June 2012
111 pages
Biofuel Industry in the United States
US$ 325.00
... from corn grain and biodiesel are the only biofuels produced in the United States on an industrial scale. Most of the four billion gallons of ... an in-depth coverage for this industry in the United States in its latest research report – Biofuel Industry in the United States. This 100 page report looks at the ...
June 2012
145 pages
Profiling the US Petroleum Refining Industry
US$ 350.00
... low quality crude oils. Aruvian Research’s report – Profiling the US Petroleum Refining Industry – analyzes the US petroleum refining industry starting from the basics. The report ...
June 2012
100 pages
Analyzing the Energy Industry in United States
US$ 450.00
... as supply strategies globally. Aruvian's R'search’s report – Analyzing the Energy Industry in United States - analyzes the scope of American energy production from varied traditional sources as well as the ...
June 2012
700 pages
Analyzing the Nuclear Power Industry in the US
US$ 400.00
The United States is the world's largest supplier of commercial nuclear power. In recent years, there has been a renewed interest in nuclear power in the US. This has been facilitated in part ...
June 2012
200 pages
Analyzing Light-Duty Hybrid-Electric Vehicles in the US
US$ 400.00
... electric vehicles are finally being sold commercially by manufacturers. The demand for light-duty hybrid-electric vehicles in the United States ... . Aruvians Rsearch analyzes the Light Duty Hybrid Electric vehicles market in the US in its research offering Analyzing Light Duty Hybrid Electric Vehicles in the US. ...
June 2012
85 pages
Analyzing the Market for Refined Petroleum Products in the US
US$ 350.00
The United States is the largest, most sophisticated producer of refined petroleum products in the world, with nearly 20 million ... , amongst others. Aruvians Rsearch analyzes the refined petroleum products market in the US in its research offering Analyzing the Market for Refined Petroleum Products in the US. ...
June 2012
105 pages
Analyzing Geothermal Power in the US
US$ 400.00
... the powerful combination of high energy prices and growing state government support. The United States Department of Energy Geothermal Technologies Program ... of development. Aruvians Rsearch analyzes the Geothermal Power in the US in its latest research offering Analyzing Geothermal Power in the US. The report ...
June 2012
195 pages
Biogen: Teriflunomide Does Not TOWER Over BG-12!
US$ 90.00
Top-line data from PhIII trial, TOWER of Sanofi’s Aubagio (teriflunomide, R, RRMS, PDUFA: 3Q12) reaffirms our take on BG-12 (Dimethyl fumerate, R, Est. ... details, please read our report released on June 1st , 2012 on Biogen (BIIB), titled “Teriflunomide Does Not TOWER Over BG-12”
May 2012
4 pages
AMGEN: Innovation + Emerging Market – A Balanced Approach!
US$ 140.00
... boosted Amgen’s (AMGN) pipeline, while Mustafa Nevzat pharma (MN pharma, pvt., Turkey) is a strategic move to increase its presence in the growing emerging/ international markets ... read our report released on May 29th, 2012 on AMGN, titled “Innovation + Emerging Market – A Balanced Approach”
May 2012
7 pages
REGENERON - Diversified Pipeline can Buffer the Setback
US$ 140.00
Despite the setback in the pipeline – negative recommendation from FDA advisory committee on ... franchise should be able to buffer some setbacks in the pipeline. The FDA advisory panel voted 11-0 against approval of the ... , released on May 14, 2012 on REGN, titled “Diversified Pipeline can Buffer the Setback”.
May 2012
6 pages
INCYTE: JAKAFI / JAKAVI to Drive Sustainable Profitability
US$ 140.00
Incyte (INCY) reported net revenues of $19.3m of the only approved drug for Myelofribrosis (MF), JAKAFI / JAKAVI (ruxolitinib, JAK 1/2 inhibitor, PhII/III in PV/ET; partnered with Novartis for ... , please read our report released on May 2, 2012 on INCY, titled “JAKAFI / JAKAVI to Drive Sustainable Profitability”
May 2012
3 pages
Analyzing the Market for Pigments in US
US$ 400.00
... few of the top players in the market. Aruvians Rsearch analyzes the Pigments market in the US in its research offering Analyzing the Market for Pigments in US. The report is a complete analysis ...
May 2012
90 pages
Analyzing the Battery Market in US
US$ 400.00
... five years. The United States is the single biggest market in the world for batteries with a market size of $5 billion annually. The US industrial market is estimated to be $600 million ...
May 2012
100 pages
Analyzing the Market for Pulp & Paper Chemicals in the US
US$ 400.00
... environmentally-friendly profiles. Aruvians Rsearch analyzes the Pulp & Paper Chemicals market in the US in its research offering Analyzing the Market for Pulp & Paper Chemicals in the US. The ...
May 2012
115 pages
CELGENE – Revlimid Sales Disappoints, but Long Term Prospects Intact!
US$ 90.00
Though Q1’12 earnings were disappointing (flat growth of Revlimid), we expect Celgene (CELG) should able to meet its FY12 guidance (Total rev.: $5.4-$5.6b ... read our report released on 27th April, 2012 on CELG titled, “Revlimid Sales Disappoints, but Long Term Prospects Intact!”
April 2012
4 pages
ALEXION: Soliris’ Label Expansion & Diversification to Perk ALXN Up!
US$ 140.00
... Hemolytic Uremic Syndrome (aHUS) indication, and label expansion in other rare and high unmet need indications of Soliris; we expect the growth trajectory continues ... , please read our report released on April 25, 2012 on ALXN, titled “Soliris’ Label Expansion & Diversification to Perk ALXN Up!”
April 2012
5 pages
2012 US Hemostasis Diagnostics Market Outlook: Growth Opportunities and Strategies
US$ 6,800.00
Report Highlights Comprehensive 424-page analysis of the US hemostasis market. Major issues pertaining to the US hemostasis laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next ten years. Ten-year volume and ...
April 2012
424 pages
